Endovascular treatment of acute limb ischemia (ALI), primarily consisting of catheter-directed thrombolysis (CDT), has been shown to reduce mortality without affecting limb salvage. Percutaneous thrombectomy (PT) devices have expanded endovascular approaches while decreasing thrombolytic use. While many advocate for an endovascular-first approach, it's unclear which patients would benefit most from each strategy. We included adults (18+) who underwent revascularization for infrainguinal ALI (01/2016-12/2023) at a multihospital healthcare system. We compared amputation and mortality after endovascular vs. open approaches using logistic regression, Kaplan-Meier curves, and cox regression. We included 315 patients: 145 undergoing an endovascular-first strategy (89 CDT, 51 PT, 5 angioplasty/stent) and 170 undergoing open therapy (132 open thrombectomy, 38 bypass). Patients undergoing endovascular-first treatment were less ischemic, had more prior stenting, and more acute-on-chronic disease. Patients undergoing PT with suction devices were less likely to undergo overnight CDT compared to those with rheolytic devices (21% vs 67%, p=0.004). There were no differences in 30-day amputation or mortality, but 30-day reintervention was increased in the endovascular group (aOR=2.29 [1.06-4.91], p=0.03). 3-year amputation rates were not significantly different on univariable or multivariable analysis when comparing the endovascular-first approach to open. PT alone trended toward increased amputation rates compared to open (aHR=1.96, 95%CI 0.98-3.94, p=0.058), however, this was mainly driven by the use of rheolytic devices with an amputation rate of 64% vs. 8% in suction devices. Furthermore, those with embolic disease had significantly increased amputation rates (aHR=2.92 [1.29-6.58], p=0.01; pinteraction=0.02) with any endovascular-first strategy, when compared to open therapy. Endovascular-first patients had decreased mortality on univariable analysis (16% vs. 37%, log-rank=0.004) but not multivariable analysis (aHR=0.60 [0.32-1.13], p=0.12). When separated by endovascular modality, CDT had decreased mortality compared to open (aHR=0.41 [0.18-0.93], p=0.033), while PT did not (aHR=1.05 [0.47-2.35], p=0.91). While effect of treatment modality on outcomes was not moderated by Rutherford classification, only 22 patients underwent endovascular-first treatment for Rutherford 2b ischemia. Endovascular-first therapy had increased 3-year amputation in patients with embolic etiology of disease compared to open therapy. We also saw increased 30-day reintervention with endovascular-first therapy when compared to open therapy. CDT had decreased 3-year mortality when compared to open therapy. PT devices had mixed results, indicating that this is a technology in evolution. Newer PT devices are effective at reducing thrombolytic usage, and their amputation and mortality rates were similar to open therapy. An endovascular-first approach to Rutherford 2b ischemia needs further evaluation.